MyFinsight
Home
Blog
About
Maturities of short-term
investments
$51,700,000
(1192.50%↑ Y/Y)
Net cash provided by
(used in) investing...
$4,115,472
(377.73%↑ Y/Y)
Canceled cashflow
$47,584,528
Net increase
(decrease) in cash and cash...
$213,503
(103.38%↑ Y/Y)
Canceled cashflow
$3,901,968
Purchase of short-term
investments
$47,584,528
(1416.14%↑ Y/Y)
Accounts payable,
accrued expenses and...
$1,559,244
(320.99%↑ Y/Y)
Stock-based compensation
expense
$1,428,451
(-45.78%↓ Y/Y)
Cash proceeds from
the issuance of...
$7,575
(-62.42%↓ Y/Y)
Net cash provided by
(used in) operating...
-$3,247,437
(51.82%↑ Y/Y)
Net cash provided by
(used in) financing...
-$647,389
(-49.68%↓ Y/Y)
Effect of exchange rate
and valuation...
-$7,142
(-174.17%↓ Y/Y)
Canceled cashflow
$2,987,695
Canceled cashflow
$7,575
Net income (loss)
-$5,313,300
(-4.62%↓ Y/Y)
Taxes paid related to
net share...
$654,964
(44.68%↑ Y/Y)
Net amortization of
investment discounts and...
$708,011
Other current assets
$213,822
(-63.56%↓ Y/Y)
Back
Back
Cash Flow
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)
source: myfinsight.com